Skip to main content
SpringerLink
Log in

Pathology of Rectal Cancer and Predictors of Response to Neoadjuvant Therapy

  • Chapter
  • First Online:
Comprehensive Rectal Cancer Care

  • 639 Accesses

Abstract

It has been reproducibly shown that rectal cancer patients managed by a multidisciplinary team of physicians yield better outcomes [1, 2]. The pathologist along with the surgeon, the medical oncologist and the radiation oncologist plays a key role in this team. The pathologist’s role is important at all stages of patient treatment; namely: the preoperative stage confirming a diagnosis of malignancy on biopsy specimens, the intraoperative stage evaluating the distal margin of resection and the postoperative stage in the examination of the surgical specimen. The anatomical extent of the disease as determined by the pathological stage, the depth of tumor infiltration into the wall of the rectum and the status of the mesorectal lymph nodes have traditionally been the most important parameters guiding postoperative treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Basta YL, Baur OL, van Dieren S, Klinkenbijl JH, Fockens P, Tytgat KM. Is there a benefit of multidisciplinary cancer team meetings for patients with gastrointestinal malignancies? Ann Surg Oncol. 2016;23(8):2430–7.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Richardson B, Preskitt J, Lichliter W, Peschka S, Carmack S, de Prisco G, Fleshman J. The effect of multidisciplinary teams for rectal cancer on delivery of care and patient outcome: has the use of multidisciplinary teams for rectal cancer affected the utilization of available resources, proportion of patients meeting the standard of care, and does this translate into changes in patient outcome? Am J Surg. 2016;211:46–52.

    Article  PubMed  Google Scholar 

  3. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence? Br J Surg. 1982;69:613–6.

    Article  CAS  PubMed  Google Scholar 

  4. Sauer R, Fietkau R, Wittekind C, Rödel C, Martus P, Hohenberger W, Tschmelitsch J, Sabitzer H, Karstens JH, Becker H, Hess C, Raab R, German Rectal Cancer Group. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. Colorectal Dis. 2003;5:406–15.

    Article  CAS  PubMed  Google Scholar 

  5. Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, O'Callaghan C, Myint AS, Bessell E, Thompson LC, Parmar M, Stephens RJ, Sebag-Montefiore D, MRC CR07/NCIC-CTG CO16 Trial Investigators, NCRI Colorectal Cancer Study Group. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet. 2009;373:821–8.

    Article  PubMed  PubMed Central  Google Scholar 

  6. García-Granero E, Faiz O, Muñoz E, Flor B, Navarro S, Faus C, García-Botello SA, Lledó S, Cervantes A. Macroscopic assessment of mesorectal excision in rectal cancer: a useful tool for improving quality control in a multidisciplinary team. Cancer. 2009;115:3400–11.

    Article  PubMed  Google Scholar 

  7. Moran B. Chapter 7. Total mesorectal excision for rectal cancer. In: Moran B, Heald RJ, editors. Manual of total mesorectal excision. Boca Raton: CRC Press; 2013. p. 103–23.

    Chapter  Google Scholar 

  8. Dayal S, Battersby N, Cecil T. Evolution of surgical treatment for rectal cancer: a review. J Gastrointest Surg. 2017;21:1166–73.

    Article  PubMed  Google Scholar 

  9. Heald RJ. The ‘holy plane’ of rectal surgery. J R Soc Med. 1988;81(9):503–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Heald R. Chapter 1. The evolution of a concept: the total mesorectal excision. In: Moran B, Heald RJ, editors. Manual of total mesorectal excision. Boca Raton: CRC Press; 2013. p. 1–30.

    Google Scholar 

  11. Nagtegaal ID, Van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken JH, Cooperative Clinical Investigators of the Dutch Colorectal Cancer Group. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol. 2002;20:1729–34.

    Google Scholar 

  12. Faus C, Roda D, Frasson M, Rosello S, Garcia-Granero E, Flor-Lorente B, Navarro S. The role of the pathologist in rectal cancer diagnosis and staging and surgical quality assessment. Clin Transl Oncol. 2010;12(5):339–45.

    Article  PubMed  Google Scholar 

  13. Zbar AP. Sir W. Ernest Miles. Tech Coloproctol. 2007;11(1):71–4.

    Article  CAS  PubMed  Google Scholar 

  14. Cole PP. The intramural spread of rectal carcinoma. Br Med J. 1913;1:431–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Scott N, Jackson P, Al-Jaberi T, Dixon MF, Quirke P, Finan PJ. Total mesorectal excision and local recurrence: a study of tumour spread in the mesorectum distal to rectal cancer. Br J Surg. 1995;82:1031–3.

    Article  CAS  PubMed  Google Scholar 

  16. Grinell RS. Distal intramural spread of carcinoma of the rectum and rectosigmoid. Surg Gynecol Obstet. 1954;99:421–30.

    Google Scholar 

  17. Williams NS, Dixon MF, Johnston D. Reappraisal of the 5 centimetre rule of distal excision for carcinoma of the rectum: a study of distal intramural spread and of patients' survival. Br J Surg. 1983;70:150–4.

    Article  CAS  PubMed  Google Scholar 

  18. Lazorthes F, Voigt JJ, Roques J, Chiotasso P, Chevreau P. Distal intramural spread of carcinoma of the rectum correlated with lymph nodal involvement. Surg Gynecol Obstet. 1990;170:45–8.

    CAS  PubMed  Google Scholar 

  19. Kiran RP, Lian L, Lavery IC. Does a subcentimeter distal resection margin adversely influence oncologic outcomes in patients with rectal cancer undergoing restorative proctectomy? Dis Colon Rectum. 2011;54:157–63.

    Article  PubMed  Google Scholar 

  20. Watanabe T, Kazama S, Nagawa H. A 1 cm distal bowel margin is safe for rectal cancer after preoperative radiotherapy. Hepato-Gastroenterology. 2012;59:1068–74.

    CAS  PubMed  Google Scholar 

  21. Guillem JG, Moore HG, Paty PB, Cohen AM, Wong WD. Adequacy of distal resection margin following preoperative combined modality therapy for rectal cancer. Ann Surg Oncol. 2003;10:824–9.

    Article  PubMed  Google Scholar 

  22. Bondeven P, Hagemann-Madsen RH, Bro L, Moran BJ, Laurberg S, Pedersen BG. Objective measurement of the distal resection margin by MRI of the fresh and fixed specimen after partial mesorectal excision for rectal cancer: 5 cm is not just 5 cm and depends on when measured. Acta Radiol. 2016;57(7):789–95.

    Article  PubMed  Google Scholar 

  23. Goldstein NS, Soman A, Sacksner J. Disparate surgical margin lengths of colorectal resection specimens between in vivo and in vitro measurements. The effects of surgical resection and formalin fixation on organ shrinkage. Am J Clin Pathol. 1999;111:349–51.

    Article  CAS  PubMed  Google Scholar 

  24. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet. 1986;2:996–9.

    Article  CAS  PubMed  Google Scholar 

  25. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26:303–12.

    Article  PubMed  Google Scholar 

  26. Hwang MR, Park JW, Park S, Yoon H, Kim DY, Chang HJ, Kim SY, Park SC, Choi HS, Oh JH, Jeong SY. Prognostic impact of circumferential resection margin in rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol. 2014;21:1345–51.

    Article  PubMed  Google Scholar 

  27. Park JS, Huh JW, Park YA, Cho YB, Yun SH, Kim HC, Lee WY, Chun HK. A circumferential resection margin of 1 mm is a negative prognostic factor in rectal cancer patients with and without neoadjuvant chemoradiotherapy. Dis Colon Rectum. 2014;57:933–40.

    Article  PubMed  Google Scholar 

  28. Nikberg M, Kindler C, Chabok A, Letocha H, Shetye J, Smedh K. Circumferential resection margin as a prognostic marker in the modern multidisciplinary management of rectal cancer. Dis Colon Rectum. 2015;58:275–82.

    Article  PubMed  Google Scholar 

  29. Hiranyakas A, da Silva G, Wexner SD, Ho YH, Allende D, Berho M. Factors influencing circumferential resection margin in rectal cancer. Color Dis. 2013;15:298–303.

    Article  CAS  Google Scholar 

  30. Al-Sukhni E, Attwood K, Gabriel E, Nurkin SJ. Predictors of circumferential resection margin involvement in surgically resected rectal cancer: a retrospective review of 23,464 patients in the US National Cancer Database. Int J Surg. 2016;28:112–7.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Hashiguchi Y, Hase K, Ueno H, Mochizuki H, Kajiwara Y, Ichikura T, Yamamoto J. Prognostic significance of the number of lymph nodes examined in colon cancer surgery: clinical application beyond simple measurement. Ann Surg. 2010;251:872–81.

    Article  PubMed  Google Scholar 

  32. Sun Z, Xu HM. Identifying the minimum number of lymph nodes required to ensure adequate pN staging: Kaplan-Meier survival analysis versus Cox regression model. Ann Surg. 2010;252(2):410–1.

    Article  PubMed  Google Scholar 

  33. Gleisner AL, Mogal H, Dodson R, Efron J, Gearhart S, Wick E, Lidor A, Herman JM, Pawlik TM. Nodal status, number of lymph nodes examined, and lymph node ratio: what defines prognosis after resection of colon adenocarcinoma? J Am Coll Surg. 2013;217:1090–100.

    Article  PubMed  Google Scholar 

  34. Arslan NC, Sokmen S, Canda AE, Terzi C, Sarioglu S. The prognostic impact of the log odds of positive lymph nodes in colon cancer. Color Dis. 2014;16:86–92.

    Article  Google Scholar 

  35. Johnson PM, Malatjalian D, Porter GA. Adequacy of nodal harvest in colorectal cancer: a consecutive cohort study. J Gastrointest Surg. 2002;6:883–8.

    Article  PubMed  Google Scholar 

  36. Topor B, Acland R, Kolodko V, Galandiuk S. Mesorectal lymph nodes: their location and distribution within the mesorectum. Dis Colon Rectum. 2003;46:779–85.

    Article  PubMed  Google Scholar 

  37. Budde CN, Tsikitis VL, Deveney KE, Diggs BS, Lu KC, Herzig DO. Increasing the number of lymph nodes examined after colectomy does not improve colon cancer staging. J Am Coll Surg. 2014;218:1004–11.

    Article  PubMed  Google Scholar 

  38. Moore J, Hyman N, Callas P, Littenberg B. Staging error does not explain the relationship between the number of lymph nodes in a colon cancer specimen and survival. Surgery. 2010;147:358–65.

    Article  PubMed  Google Scholar 

  39. Nedrebø BS, Søreide K, Nesbakken A, et al. Risk factors associated with poor lymph node harvest after colon cancer surgery in a national cohort. Color Dis. 2013;15(6):e301–8.

    Article  Google Scholar 

  40. Moro-Valdezate D, Pla-Martí V, Martín-Arévalo J, et al. Factors related to lymph node harvest: does a recovery of more than 12 improve the outcome of colorectal cancer? Color Dis. 2013;15(10):1257–66.

    Article  CAS  Google Scholar 

  41. Doll D, Gertler R, Maak M, Friederichs J, Becker K, Geinitz H, Kriner M, Nekarda H, Siewert JR. Reduced lymph node yield in rectal carcinoma specimen after neoadjuvant radiochemotherapy. World J Surg. 2009;33(2):340–7.

    Article  PubMed  Google Scholar 

  42. Bollschweiler E, Besch S, Drebber U, Schröder W, Mönig SP, Vallböhmer D, Baldus SE, Metzger R, Hölscher AH. Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer. Ann Surg Oncol. 2010;17:3187–94.

    Article  PubMed  Google Scholar 

  43. Amajoyi R, Lee Y, Recio PJ, Kondylis PD. Neoadjuvant therapy for rectal cancer decreases the number of lymph nodes harvested in operative specimens. Am J Surg. 2013;205:289–92.

    Article  PubMed  Google Scholar 

  44. Yegen G, Keskin M, Büyük M, Kunduz E, Balık E, Sağlam EK, Kapran Y, Asoğlu O, Güllüoğlu M. The effect of neoadjuvant therapy on the size, number, and distribution of mesorectal lymph nodes. Ann Diagn Pathol. 2016;20:29–35.

    Article  PubMed  Google Scholar 

  45. Habr-Gama A, Perez RO, Proscurshim I, Rawet V, Pereira DD, Sousa AH, Kiss D, Cecconello I. Absence of lymph nodes in the resected specimen after radical surgery for distal rectal cancer and neoadjuvant chemoradiation therapy: what does it mean? Dis Colon Rectum. 2008;51:277–83.

    Article  PubMed  Google Scholar 

  46. Kim WR, Han YD, Cho MS, Hur H, Min BS, Lee KY, Kim NK. Oncologic impact of fewer than 12 lymph nodes in patients who underwent neoadjuvant chemoradiation followed by total mesorectal excision for locally advanced rectal cancer. Medicine. 2015;94:e1133.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Wang H, Safar B, Wexner SD, Denoya P, Berho M. The clinical significance of fat clearance lymph node harvest for invasive rectal adenocarcinoma following neoadjuvant therapy. Dis Colon Rectum. 2009;52:1767–73.

    Article  PubMed  Google Scholar 

  48. Mechera R, Schuster T, Rosenberg R, Speich B. Lymph node yield after resection in patients treated with neoadjuvant radiation for rectal cancer: a systematic review and meta-analysis. Eur J Cancer. 2017;72:84–94.

    Article  PubMed  Google Scholar 

  49. Cawthorn SJ, Gibbs NM, Marks CG. Clearance technique for the detection of lymph nodes in colorectal cancer. Br J Surg. 1986;73:58–60.

    Article  CAS  PubMed  Google Scholar 

  50. Cohen SM, Wexner SD, Schmitt SL, et al. Effect of xylene clearance of mesenteric fat on harvest of lymph nodes after colonic resection. Eur J Surg. 1994;160:693–7.

    CAS  PubMed  Google Scholar 

  51. Sanchez W, Luna-Perez P, Alvarado I, et al. Modified clearing technique to identify lymph node metastases in post-irradiated surgical specimens from rectal adenocarcinomas. Arch Med Res. 1996;27:31–6.

    CAS  PubMed  Google Scholar 

  52. Jung M, Shin SJ, Koom WS, Jung I, Keum KC, Hur H, Min BS, Baik SH, Kim NK, Kim H, Lim JS, Hong SP, Kim TI, Roh JK, Park YS, Ahn JB. A randomized phase 2 study of neoadjuvant chemoradiaton therapy with 5-fluorouracil/leucovorin or irinotecan/S-1 in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2015;93:1015–22.

    Article  CAS  PubMed  Google Scholar 

  53. Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst. 2015;107:1–8.

    Google Scholar 

  54. Kulu Y, Tarantino I, Billeter AT, Diener MK, Schmidt T, Büchler MW, Ulrich A. Comparative outcomes of neoadjuvant treatment prior to total mesorectal excision and total mesorectal excision alone in selected stage II/III low and mid rectal cancer. Ann Surg Oncol. 2016;23:106–13.

    Article  PubMed  Google Scholar 

  55. Lefevre JH, Rousseau A, Svrcek M, Parc Y, Simon T, Tiret E, French Research Group of Rectal Cancer Surgery (GRECCAR). A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): rationale and design. BMC Cancer. 2013;13:417. (1–8)

    Article  PubMed  PubMed Central  Google Scholar 

  56. Glynne-Jones R, Hughes R. Complete response after chemoradiotherapy in rectal cancer (watch-and-wait): have we cracked the code? Clin Oncol (R Coll Radiol). 2016;28:152–60.

    Article  CAS  Google Scholar 

  57. Wasmuth HH, Rekstad LC, Tranø G. The outcome and the frequency of pathological complete response after neoadjuvant radiotherapy in curative resections for advanced rectal cancer: a population-based study. Color Dis. 2016;18:67–72.

    Article  CAS  Google Scholar 

  58. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;1(73):2680–6.

    Article  Google Scholar 

  59. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Color Dis. 1997;12(1):19–23.

    Article  CAS  Google Scholar 

  60. Mace AG, Pai RK, Stocchi L, Kalady MF. American Joint Committee on Cancer and College of American Pathologists regression grade: a new prognostic factor in rectal cancer. Dis Colon Rectum. 2015;58:32–44.

    Article  PubMed  Google Scholar 

  61. Perez RO. Why do we need another tumor regression grading system for rectal cancer after neoadjuvant therapy? Dis Colon Rectum. 2015;58:1–2.

    Article  PubMed  Google Scholar 

  62. Jäger T, Neurieiter D, Urbas R, Klieser E, Hitzl W, Emmanuel K, Dinnewitzer A. Applicability of American Joinr Committee on Cancer and College of American Pathologists Regression Grading System in rectal cancer. Dis Colon Rectum. 2017;60:815–26.

    Article  PubMed  Google Scholar 

  63. Chetty R, Gill P, Govender D, Bateman A, Chang HJ, Deshpande V, Driman D, Gomez M, Greywoode G, Jaynes E, Lee CS, Locketz M, Rowsell C, Rullier A, Serra S, Shepherd N, Szentgyorgyi E, Vajpeyi R, Wang LM, Bateman A. International study group on rectal cancer regression grading: interobserver variability with commonly used regression grading systems. Hum Pathol. 2012;43(11):1917–23.

    Article  PubMed  Google Scholar 

  64. Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M, Pucciarelli S, Small W Jr, Suárez J, Theodoropoulos G, Biondo S, Beets-Tan RG, Beets GL. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44.

    Article  PubMed  Google Scholar 

  65. Hermanek P, Merkel S, Hohenberger W. Prognosis of rectal carcinoma after multimodal treatment: ypTNM classification and tumor regression grading are essential. Anticancer Res. 2013;33:559–66.

    PubMed  Google Scholar 

  66. Tural D, Selcukbiricik F, Özturk MA, Yildiz O, Turna H, Erdamar S, Büyükünal E, Serdengeçti S. The relation between pathological complete response and clinical outcome in patients with rectal cancer. Hepato-Gastroenterology. 2013;60:1365–70.

    PubMed  Google Scholar 

  67. Dinaux AM, Amri R, Bordeianou LG, Hong TS, Wo JY, Blaszkowsky LS, Allen JN, Murphy JE, Kunitake H, Berger DL. The impact of pathologic complete response in patients with neoadjuvantly treated locally advanced rectal cancer-a large single-center experience. J Gastrointest Surg. 2017;21(7):1153–8.

    Article  CAS  PubMed  Google Scholar 

  68. Hugen N, van de Velde CJH, de Wilt JHW, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014;25:651–7.

    Google Scholar 

  69. Lin HH, Yang HL, Lin JK, Lin CC, Wang HS, Yang SH, Jiang JK, Lan YT, Lin TC, Chen WS, Liang WY, Chang SC. The number of risk factors determines the outcome of stage II colorectal cancer patients. Hepato-Gastroenterology. 2014;61:1024–7.

    PubMed  Google Scholar 

  70. Chablani P, Nguyen P, Pan X, Robinson A, Walston S, Wu C, Frankel WL, Chen W, Bekaii-Saab T, Chakravarti A, Wuthrick E, Williams TM. Perineural invasion predicts for distant metastasis in locally advanced rectal cancer treated with neoadjuvant chemoradiation and surgery. Am J Clin Oncol. 2017;40(6):561–8.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Cienfuegos JA, Rotellar F, Baixauli J, Beorlegui C, Sola JJ, Arbea L, Pastor C, Arredondo J, Hernández-Lizoáin JL. Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery. Ann Surg Oncol. 2015;22:916–23.

    Article  CAS  PubMed  Google Scholar 

  72. Lankshear S, Srigley J, McGowan T, Yurcan M, Sawka C. Standardized synoptic cancer pathology reports – so what and who cares? A population-based satisfaction survey of 970 pathologists, surgeons, and oncologists. Arch Pathol Lab Med. 2013;137:1599–602.

    Article  PubMed  Google Scholar 

  73. Ihnát P, Delongová P, Horáček J, Ihnát Rudinská L, Vávra P, Zonča P. The impact of standard protocol implementation on the quality of colorectal cancer pathology reporting. World J Surg. 2015;39(1):259–65.

    Article  PubMed  Google Scholar 

  74. Littleford SE, Baird A, Rotimi O, et al. Interobserver variation in the reporting of local peritoneal involvement and extramural venous invasion in colonic cancer. Histopathology. 2009;55:407–13.

    Article  PubMed  Google Scholar 

  75. Messenger DE, Driman DK, Kirsch R. Developments in the assessment of venous invasion in colorectal cancer: implications for future practice and patient outcome. Hum Pathol. 2012;43:965–73.

    Article  PubMed  Google Scholar 

  76. Lai YH, Wu LC, Li PS, Wu WH, Yang SB, Xia P, He XX, Xiao LB. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer. Color Dis. 2014 Apr;16(4):259–64.

    Article  Google Scholar 

  77. Jayasinghe C, Simiantonaki N, Kirkpatrick CJ. Histopathological features predict metastatic potential in locally advanced colon carcinomas. BMC Cancer. 2015;15:1013–7.

    Article  CAS  Google Scholar 

  78. Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer--ready for diagnostic practice? Hum Pathol. 2016;47:4–19.

    Article  PubMed  Google Scholar 

  79. Garcia Solano J, Conesa Zamora P, Trujillo-Santos J, Torres-Moreno D, Makinen MJ, Perez-Guillermo M. Immunohistochemical expression profile of beta-catenin, e-cadherin, p-cadherin, laminin-5y2 chain and SMAD4 in colorectal serrated adenocarcinoma. Hum Pathol. 2012;43:1094–102.

    Article  CAS  PubMed  Google Scholar 

  80. Dawson H, Lugli A. Molecular and pathogenetic aspects of tumor budding in colorectal cancer. Front Med (Lausanne). 2015;2:1–11.

    Google Scholar 

  81. Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Ward RL, Cheong K, Sl K, Meagher A, O’Connor T, Hawkins NJ. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol. 2003;21:3729–36.

    Article  CAS  PubMed  Google Scholar 

  83. Sepulveda AR, Hamilton SR, Allegra CJ. Molecular biomarkers for the evaluation of colorectal cáncer. Guideline from the American Society of Clinical Pathology, College of American Pathologists, Association for Molecular Pathology and American Society of Clinical Pathology. Arch Pathol Lab Med. 2017;141:625–57.

    Article  PubMed  Google Scholar 

  84. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol Mech Dis. 2011;6:479–507.

    Article  CAS  Google Scholar 

  85. Snowsill T, Coelho H, Huxley N, Jones-Hughes T, Briscoe S, Frayling IM, Hyde C. Molecular testing for lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. Health Technoil Assess. 2017;21(51):1–238.

    Article  Google Scholar 

  86. Umar A, Boland R, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.

    Article  CAS  PubMed  Google Scholar 

  87. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as predictor of benefit from fluorauracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Birgisson H, Edlund K, Wallin U, Påhlman L, Kultima HG, Mayrhofer M, Micke P, Isaksson A, Botling J, Glimelius B, Sundström M. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. BMC Cancer. 2015;15:125. (1–11)

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  89. Lin CC, Lin JK, Lin TC, Chen WS, Yang SH, Wang HS, Lan YT, Jiang JK, Yang MH, Chang SC. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer. J Surg Oncol. 2014;110:451–7.

    Article  CAS  PubMed  Google Scholar 

  90. Modest DP, Ricard I, Heinemann V. Outcome according to KRAS-NRAS and BRAF mutation as well as KRAS mutation variants in colon cáncer. J Surg Oncol. 2014;110:451–7.

    Article  CAS  Google Scholar 

  91. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012;18(3):890–900.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Cleveland Clinic Florida, Weston, FL, USA

    Mariana Berho & Pablo Bejarano

Authors
  1. Mariana Berho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pablo Bejarano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mariana Berho .

Editor information

Editors and Affiliations

  1. University of California, Los Angeles, Los Angeles, CA, USA

    Mary Kwaan

  2. University of Melbourne, Victoria, VIC, Australia

    Andrew Zbar

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Berho, M., Bejarano, P. (2019). Pathology of Rectal Cancer and Predictors of Response to Neoadjuvant Therapy. In: Kwaan, M., Zbar, A. (eds) Comprehensive Rectal Cancer Care. Springer, Cham. https://doi.org/10.1007/978-3-319-98902-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98902-0_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98901-3

  • Online ISBN: 978-3-319-98902-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation